This seventh issue of our DDup (Drug Discovery Update) is dedicated to our highly innovative iPSC (induced pluripotent stem cell) platform, which we started developing more than six years ago with the goal to industrialize iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach highest industrial standards. Today, it represents one of the largest and most sophisticated iPSC platforms in the industry and plays an essential role in iPSC alliances with strategic partners, such as Celgene and Sanofi.

Download this Drug Discovery Update #8 to learn more about our iPSC Platform, Bank, and Automation, along with our CRISPR-based platform, transcriptomics, proteomics & metabolomics and disease modeling capabilities.